First clinical data for monalizumab as a single agent in cancer patients show favorable safety profile
Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (Nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck
Innate Pharma investor conference call on November 14, 2016 to discuss recent new clinical data
Preliminary Phase 1/2 efficacy data of Lirilumab in combination with Opdivo (Nivolumab) in patients with advanced platinum refractory squamous cell carcinoma of the head and neck to be presented during SITC meeting
Third quarter 2016 report
Encouraging initial results for IPH4102 presented at the Third World Congress of Cutaneous Lymphomas
Preliminary safety and clinical activity results for IPH4102 to be presented at the Third World Congress of Cutaneous Lymphomas
Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress
Safety data for Lirilumab in combination with Nivolumab or Ipilimumab to be presented at the ESMO 2016 Congress
Seventh data and Safety Monitoring Board Meeting of the EffiKIR trial recommends continuation without modification
